243 related articles for article (PubMed ID: 23701009)
1. Exploring structural requirements for a class of nucleoside inhibitors (PfdUTPase) as antimalarials: first report on QSAR, pharmacophore mapping and multiple docking studies.
Ojha PK; Roy K
Comb Chem High Throughput Screen; 2013 Nov; 16(9):739-57. PubMed ID: 23701009
[TBL] [Abstract][Full Text] [Related]
2. dUTPase as a platform for antimalarial drug design: structural basis for the selectivity of a class of nucleoside inhibitors.
Whittingham JL; Leal I; Nguyen C; Kasinathan G; Bell E; Jones AF; Berry C; Benito A; Turkenburg JP; Dodson EJ; Ruiz Perez LM; Wilkinson AJ; Johansson NG; Brun R; Gilbert IH; Gonzalez Pacanowska D; Wilson KS
Structure; 2005 Feb; 13(2):329-38. PubMed ID: 15698576
[TBL] [Abstract][Full Text] [Related]
3. 3D QSAR, pharmacophore and molecular docking studies of known inhibitors and designing of novel inhibitors for M18 aspartyl aminopeptidase of Plasmodium falciparum.
Kumari M; Chandra S; Tiwari N; Subbarao N
BMC Struct Biol; 2016 Aug; 16():12. PubMed ID: 27534744
[TBL] [Abstract][Full Text] [Related]
4. Exploring QSAR, pharmacophore mapping and docking studies and virtual library generation for cycloguanil derivatives as PfDHFR-TS inhibitors.
Ojha PK; Roy K
Med Chem; 2011 May; 7(3):173-99. PubMed ID: 21486210
[TBL] [Abstract][Full Text] [Related]
5. First report on exploring structural requirements of α and β thymidine analogs for PfTMPK inhibitory activity using in silico studies.
Ojha PK; Roy K
Biosystems; 2013 Sep; 113(3):177-95. PubMed ID: 23850534
[TBL] [Abstract][Full Text] [Related]
6. Understanding the structural requirements in diverse scaffolds for the inhibition of P. falciparum dihydroorotate dehydrogenase (PfDHODH) using 2D-QSAR, 3D-pharmacophore and structure-based energy- optimized pharmacophore models.
Aher RB; Roy K
Comb Chem High Throughput Screen; 2015; 18(2):217-26. PubMed ID: 25543684
[TBL] [Abstract][Full Text] [Related]
7. β-Branched acyclic nucleoside analogues as inhibitors of Plasmodium falciparum dUTPase.
Baragaña B; McCarthy O; Sánchez P; Bosch-Navarrete C; Kaiser M; Brun R; Whittingham JL; Roberts SM; Zhou XX; Wilson KS; Johansson NG; González-Pacanowska D; Gilbert IH
Bioorg Med Chem; 2011 Apr; 19(7):2378-91. PubMed ID: 21411327
[TBL] [Abstract][Full Text] [Related]
8. Identification of novel PfDHODH inhibitors as antimalarial agents via pharmacophore-based virtual screening followed by molecular docking and in vivo antimalarial activity.
Vyas VK; Qureshi G; Ghate M; Patel H; Dalai S
SAR QSAR Environ Res; 2016 Jun; 27(6):427-40. PubMed ID: 27310104
[TBL] [Abstract][Full Text] [Related]
9. Site-directed mutagenesis provides insights into the selective binding of trityl derivatives to Plasmodium falciparum dUTPase.
Recio E; Musso-Buendía A; Vidal AE; Ruda GF; Kasinathan G; Nguyen C; Ruiz-Pérez LM; Gilbert IH; González-Pacanowska D
Eur J Med Chem; 2011 Aug; 46(8):3309-14. PubMed ID: 21600680
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and evaluation of novel uracil acetamide derivatives as potential inhibitors of Plasmodium falciparum dUTP nucleotidohydrolase.
McCarthy O; Musso-Buendia A; Kaiser M; Brun R; Ruiz-Perez LM; Johansson NG; Pacanowska DG; Gilbert IH
Eur J Med Chem; 2009 Feb; 44(2):678-88. PubMed ID: 18619713
[TBL] [Abstract][Full Text] [Related]
11. Multiple e-pharmacophore modelling pooled with high-throughput virtual screening, docking and molecular dynamics simulations to discover potential inhibitors of Plasmodium falciparum lactate dehydrogenase (PfLDH).
Saxena S; Durgam L; Guruprasad L
J Biomol Struct Dyn; 2019 Apr; 37(7):1783-1799. PubMed ID: 29718775
[TBL] [Abstract][Full Text] [Related]
12. Comparative study between 3D-QSAR and Docking-Based Pharmacophore models for potent Plasomodium falciparum dihydroorotate dehydrogenase inhibitors.
Tseng TS; Lee YC; Hsiao NW; Liu YR; Tsai KC
Bioorg Med Chem Lett; 2016 Jan; 26(2):265-271. PubMed ID: 26707392
[TBL] [Abstract][Full Text] [Related]
13. QSAR and pharmacophore modeling of natural and synthetic antimalarial prodiginines.
Singh B; Vishwakarma RA; Bharate SB
Curr Comput Aided Drug Des; 2013 Sep; 9(3):350-9. PubMed ID: 24010933
[TBL] [Abstract][Full Text] [Related]
14. Exploring the structural requirements in multiple chemical scaffolds for the selective inhibition of Plasmodium falciparum calcium-dependent protein kinase-1 (PfCDPK-1) by 3D-pharmacophore modelling, and docking studies.
Aher RB; Roy K
SAR QSAR Environ Res; 2017 May; 28(5):390-414. PubMed ID: 28562086
[TBL] [Abstract][Full Text] [Related]
15. QSAR, docking and ADMET studies of artemisinin derivatives for antimalarial activity targeting plasmepsin II, a hemoglobin-degrading enzyme from P. falciparum.
Qidwai T; Yadav DK; Khan F; Dhawan S; Bhakuni RS
Curr Pharm Des; 2012; 18(37):6133-54. PubMed ID: 22670592
[TBL] [Abstract][Full Text] [Related]
16. First report on exploring structural requirements of 1,2,3,4- tetrahydroacridin-9(10H)-one analogs as antimalarials using multiple QSAR approaches: descriptor-based QSAR, CoMFA-CoMSIA 3DQSAR, HQSAR and G-QSAR approaches.
Ojha PK; Roy K
Comb Chem High Throughput Screen; 2013 Jan; 16(1):7-21. PubMed ID: 23127758
[TBL] [Abstract][Full Text] [Related]
17. Validation of Plasmodium falciparum dUTPase as the target of 5'-tritylated deoxyuridine analogues with anti-malarial activity.
Pérez-Moreno G; Sánchez-Carrasco P; Ruiz-Pérez LM; Johansson NG; Müller S; Baragaña B; Hampton SE; Gilbert IH; Kaiser M; Sarkar S; Pandurangan T; Kumar V; González-Pacanowska D
Malar J; 2019 Dec; 18(1):392. PubMed ID: 31796083
[TBL] [Abstract][Full Text] [Related]
18. In silico identification of promiscuous scaffolds as potential inhibitors of 1-deoxy-d-xylulose 5-phosphate reductoisomerase for treatment of Falciparum malaria.
Wadood A; Ghufran M; Hassan SF; Khan H; Azam SS; Rashid U
Pharm Biol; 2017 Dec; 55(1):19-32. PubMed ID: 27650666
[TBL] [Abstract][Full Text] [Related]
19. Classification SAR modeling of diverse quinolone compounds for antimalarial potency against Plasmodium falciparum.
Aher RB; Roy K
Comb Chem High Throughput Screen; 2014; 17(5):396-406. PubMed ID: 24372050
[TBL] [Abstract][Full Text] [Related]
20. Targeting malaria with specific CDK inhibitors.
Geyer JA; Prigge ST; Waters NC
Biochim Biophys Acta; 2005 Dec; 1754(1-2):160-70. PubMed ID: 16185941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
